Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Reshma Rangwala
Aravive Biologics, Inc.
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
19
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Phase 1b Study of Batiraxcept (AVB-S6-500) in Combination with Durvalumab (MEDI4736) in Patients with Platinum-Resistant Ovarian Cancer
Number of pages: 27
Posted: 01 Feb 2024
Anne Knisely
,
Emily M. Hinchcliff
,
Elisabeth Gardiner
, Reshma Rangwala,
Kathryn Lito
,
Bryan Fellman
,
Ying Yuan
,
Anil Sood
,
Shannon N. Westin
,
Karen H. Lu
and
Amir A. Jazaeri
University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Aravive Biologics, Inc., Aravive Biologics, Inc., University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine and University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine
Downloads
19
(1,459,862)
View PDF
Download
Abstract:
immune checkpoint inhibitor, AXL inhibitor, Batiraxcept, platinum-resistant ovarian cancer
Feedback
